메뉴 건너뛰기




Volumn 19, Issue SUPPL. 3, 2012, Pages

Plea for advancement of the age of vaccination against human papillomavirus in France. Position of the Pediatric Infections Pathology Group (GPIP) and the French Association of Ambulatory Pediatrics (AFPA);Plaidoyer pour un avancement de l'âge de la vaccination contre les papillomavirus en France. Position du Groupe de Pathologie Infectieuse Pédiatrique (GPIP) et de l'Association Française de Pédiatrie Ambulatoire (AFPA)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

EID: 84869764751     PISSN: 0929693X     EISSN: 1769664X     Source Type: Journal    
DOI: 10.1016/S0929-693X(12)71289-7     Document Type: Article
Times cited : (1)

References (24)
  • 1
    • 84871501913 scopus 로고    scopus 로고
    • Avis du Comité Technique des Vaccinations et du Conseil Supérieur d'hygiène Publique de France (section des maladies transmissibles) relatif à la vaccination contre les papillomavirus humains 6, 11, 16 et 18 (séances du 9 mars
    • Avis du Comité Technique des Vaccinations et du Conseil Supérieur d'hygiène Publique de France (section des maladies transmissibles) relatif à la vaccination contre les papillomavirus humains 6, 11, 16 et 18 (séances du 9 mars 2007).
    • (2007)
  • 2
    • 79959765563 scopus 로고    scopus 로고
    • End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age
    • Castellsague X., Munoz N., Pitisuttithum P., et al. End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age. Br J Cancer 2011, 105:28-37.
    • (2011) Br J Cancer , vol.105 , pp. 28-37
    • Castellsague, X.1    Munoz, N.2    Pitisuttithum, P.3
  • 4
    • 84871482926 scopus 로고    scopus 로고
    • Gardasil European Public Assessment Report GARDASIL:
    • Gardasil European Public Assessment Report GARDASIL: http://www.emea.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000703/WC500021142.pdf.
  • 5
    • 84871506021 scopus 로고    scopus 로고
    • Cervarix European Public Assessment Report:
    • Cervarix European Public Assessment Report: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000721/WC500024632.pdf.
  • 7
    • 84871480792 scopus 로고    scopus 로고
    • http://www.inpes.sante.fr/30000/actus2012/027-hbsc.asp.
  • 8
    • 79955034694 scopus 로고    scopus 로고
    • HPV vaccination in France: uptake, costs and issues for the National Health Insurance
    • Fagot J.P., Boutrelle A., Ricordeau P., et al. HPV vaccination in France: uptake, costs and issues for the National Health Insurance. Vaccine 2011, 29:3610-3616.
    • (2011) Vaccine , vol.29 , pp. 3610-3616
    • Fagot, J.P.1    Boutrelle, A.2    Ricordeau, P.3
  • 9
    • 84861195608 scopus 로고    scopus 로고
    • Couverture vaccinale : Les ados en danger... Le point à l'occasion de la semaine de la vaccination
    • Cohen R., Denis F., Gaudelus J., et al. Couverture vaccinale : Les ados en danger... Le point à l'occasion de la semaine de la vaccination. Med Mal Infect 2012, 42:139-140.
    • (2012) Med Mal Infect , vol.42 , pp. 139-140
    • Cohen, R.1    Denis, F.2    Gaudelus, J.3
  • 10
    • 36749010976 scopus 로고    scopus 로고
    • Human papilloma virus immunization in adolescent and young adults: a cohort study to illustrate what events might be mistaken for adverse reactions
    • Siegrist C.A., Lewis E.M., Eskola J., et al. Human papilloma virus immunization in adolescent and young adults: a cohort study to illustrate what events might be mistaken for adverse reactions. Pediatr Infect Dis J 2007, 26:979-984.
    • (2007) Pediatr Infect Dis J , vol.26 , pp. 979-984
    • Siegrist, C.A.1    Lewis, E.M.2    Eskola, J.3
  • 11
    • 0029025444 scopus 로고
    • Immunization with virus like particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection
    • Breitburd F., Kirnbauer R., Hubbert N.L., et al. Immunization with virus like particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol 1995, 69:3959-3963.
    • (1995) J Virol , vol.69 , pp. 3959-3963
    • Breitburd, F.1    Kirnbauer, R.2    Hubbert, N.L.3
  • 12
    • 0029610072 scopus 로고
    • Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas
    • Suzich J.A., Ghim S.J., Palmer-Hill F.J., et al. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci USA 1995, 92:11553-11557.
    • (1995) Proc Natl Acad Sci USA , vol.92 , pp. 11553-11557
    • Suzich, J.A.1    Ghim, S.J.2    Palmer-Hill, F.J.3
  • 13
    • 35348908938 scopus 로고    scopus 로고
    • Impact of baseline covariates on the immunogenicity of a quadrivalent (types 6, 11, 16, and 18) human papillomavirus virus-like-particle vaccine
    • Giuliano A.R., Lazcano-Ponce E., Villa L., et al. Impact of baseline covariates on the immunogenicity of a quadrivalent (types 6, 11, 16, and 18) human papillomavirus virus-like-particle vaccine. J Infect Dis 2007, 196:1153-1162.
    • (2007) J Infect Dis , vol.196 , pp. 1153-1162
    • Giuliano, A.R.1    Lazcano-Ponce, E.2    Villa, L.3
  • 14
    • 34248631118 scopus 로고    scopus 로고
    • Immunization of early adolescent females with human papillomavirus type 6 and 18 L1 virus-like particle vaccine containing AS04 adjuvant
    • Pedersen C., Petaja T., Strauss G., et al. Immunization of early adolescent females with human papillomavirus type 6 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. J Adolesc Health 2007, 40:564-571.
    • (2007) J Adolesc Health , vol.40 , pp. 564-571
    • Pedersen, C.1    Petaja, T.2    Strauss, G.3
  • 15
    • 84855184271 scopus 로고    scopus 로고
    • Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared to the licensed 3-dose schedule: Results from a randomized study
    • Romanowski B., Schwarz T.F., Ferguson L.M., et al. Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared to the licensed 3-dose schedule: Results from a randomized study. Hum Vaccin 2011, 7:1374-1386.
    • (2011) Hum Vaccin , vol.7 , pp. 1374-1386
    • Romanowski, B.1    Schwarz, T.F.2    Ferguson, L.M.3
  • 16
    • 79952567170 scopus 로고    scopus 로고
    • Human papillomavirus 16 (HPV 16) and HPV 18 antibody responses measured by pseudovirus neutralization and competitive luminex assays in a two-versus three-dose HPV vaccine trial
    • Krajden M., Cook D., Yu A., et al. Human papillomavirus 16 (HPV 16) and HPV 18 antibody responses measured by pseudovirus neutralization and competitive luminex assays in a two-versus three-dose HPV vaccine trial. Clin Vaccine Immunol 2011, 18:418-423.
    • (2011) Clin Vaccine Immunol , vol.18 , pp. 418-423
    • Krajden, M.1    Cook, D.2    Yu, A.3
  • 17
    • 84855330556 scopus 로고    scopus 로고
    • Success of HPV vaccination is now a matter of coverage
    • Schiffman M., Wacholder S. Success of HPV vaccination is now a matter of coverage. Lancet Oncol 2012, 13:10-12.
    • (2012) Lancet Oncol , vol.13 , pp. 10-12
    • Schiffman, M.1    Wacholder, S.2
  • 18
    • 84865012403 scopus 로고    scopus 로고
    • Vaccinoscopie : Couverture vaccinale vis à vis du méningo C
    • Gaudelus J., Cohen R., Lepetit H., et al. Vaccinoscopie : Couverture vaccinale vis à vis du méningo C. Médecine et Enfance 2011, 11:205-209.
    • (2011) Médecine et Enfance , vol.11 , pp. 205-209
    • Gaudelus, J.1    Cohen, R.2    Lepetit, H.3
  • 19
    • 84861742303 scopus 로고    scopus 로고
    • Human papillomavirus - associated cancers - United States 2004-2008
    • Centers for Disease Control and prevention (CDC)
    • Human papillomavirus - associated cancers - United States 2004-2008. MMWR Mord Mortal Wkly 2012, 61:258-261. Centers for Disease Control and prevention (CDC).
    • (2012) MMWR Mord Mortal Wkly , vol.61 , pp. 258-261
  • 20
    • 80054087108 scopus 로고    scopus 로고
    • Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine
    • for the CVT Vaccine Group
    • Kreimer A.R., Rodriguez A.C., Hildesheim A., et al. Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst 2011, 103:1444-1451. for the CVT Vaccine Group.
    • (2011) J Natl Cancer Inst , vol.103 , pp. 1444-1451
    • Kreimer, A.R.1    Rodriguez, A.C.2    Hildesheim, A.3
  • 21
    • 84871494600 scopus 로고    scopus 로고
    • http://afssaps-prd.afssaps.fr/php/ecodex/rcp/R0134370.htm.
  • 22
    • 84871514532 scopus 로고    scopus 로고
    • Office fédéral de Santé publique - Plan de vaccination suisse
    • Office fédéral de Santé publique - Plan de vaccination suisse 2012 : http://www.bag.admin.ch/ekif/04423/04428/index.html%3Flang=frhttp%3A//www.bag.admin.ch/ekif/04423/04428/index.html%3Flang=fr.
    • (2012)
  • 23
    • 84871501914 scopus 로고    scopus 로고
    • Call for evidence to support HPV immunisation programme review
    • Call for evidence to support HPV immunisation programme review http://www.dh.gov.uk/health/2012/08/jcvi-hpv/.
  • 24
    • 84869811234 scopus 로고    scopus 로고
    • ECDC Guidance: Introduction of HPV vaccines in European Union countries - an update September
    • ECDC Guidance: Introduction of HPV vaccines in European Union countries - an update September 2012.
    • (2012)


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.